Phase II multicentre open label trial evaluating the efficacy and safety of the liopsomal doxorubicin (Myocet) and docetaxel (Taxotere) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

Trial Profile

Phase II multicentre open label trial evaluating the efficacy and safety of the liopsomal doxorubicin (Myocet) and docetaxel (Taxotere) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2011

At a glance

  • Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms MYOTAX
  • Most Recent Events

    • 18 Nov 2009 Actual number of patients (70) added and trial sponsor changed from Zeneus Pharma to Cephalon as reported by ClinicalTrials.gov
    • 17 Nov 2009 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov
    • 17 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top